Transfusion with human derived or recombinant clotting factors can rapidly normalize the INR. However, this treatment is expensive, inconvenient, associated with infectious or other complications such as allergy or thrombosis, and has never been prospectively studied in non-bleeding patients (9). Thus, transfusion therapy should not be used to correct an excessively prolonged INR value in non-bleeding patients.